ArticleProceedings of the National Academy of Sciences of the United States of America2003
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 3 syntheses or guidelines pooled it, 456 citations in OpenAlex.
- Asthma and increased carotid intima-media thickness: A systematic review and meta-analysis.Biomolecules & biomedicine · 2026Pooled it
- Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- 5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort.Journal of the American Heart Association · 2016Pooled it
- Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.Clinical pharmacology in drug development · 2020Trial
- Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5-Lipoxygenase Activating Protein Inhibitor.Clinical and translational science · 2018Trial
- Effect of treatment with 5-lipoxygenase inhibitor VIA-2291 (atreleuton) on coronary plaque progression: a serial CT angiography study.Clinical cardiology · 2017Trial
- Common Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Incident Myocardial Infarction: A Danish Case-Cohort Study.PloS one · 2016Trial
- Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.Cancer prevention research (Philadelphia, Pa.) · 2013Trial
- Functional analysis of 5-lipoxygenase promoter repeat variants.Human molecular genetics · 2009Trial
- Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.Cancer prevention research (Philadelphia, Pa.) · 2009Trial
- Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).Journal of leukocyte biology · 2026Article
- Association of estimated pulse wave velocity with asthma risk in middle-aged and older adults in China: a national cohort study.BMC public health · 2025Article
- Causal Relationship Between Serum Uric Acid and Atherosclerotic Disease: A Mendelian Randomization and Transcriptomic Analysis.Biomedicines · 2025Article
- Disposition of orally administered atuliflapon, a novel 5-lipoxygenase-activating protein inhibitor in healthy participants.Pharmacology research & perspectives · 2024Article
- Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance.BMC medical genomics · 2024Article
- Genetic Evidence for Causal Relationships between Plasma Eicosanoid Levels and Cardiovascular Disease.Metabolites · 2024Article
- Article
- Systemic Inflammation in Asthma: What Are the Risks and Impacts Outside the Airway?The journal of allergy and clinical immunology. In practice · 2024Review
- Targeting leukotriene biosynthesis to prevent atherosclerotic cardiovascular disease.Conditioning medicine · 2023Article
- The diverse roles of macrophages in metabolic inflammation and its resolution.Frontiers in cell and developmental biology · 2023Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidation products of low-density lipoproteins have been suggested to promote inflammation during atherogenesis, and reticulocyte-type 15-lipoxygenase has been implicated to mediate this oxidation. In addition, the 5-lipoxygenase cascade leads to formation of leukotrienes, which exhibit strong proinflammatory activities in cardiovascular tissues. Here, we studied both lipoxygenase pathways in human atherosclerosis. The 5-lipoxygenase pathway was abundantly expressed in arterial walls of patients afflicted with various lesion stages of atherosclerosis of the aorta and of coronary and carotid arteries. 5-lipoxygenase localized to macrophages, dendritic cells, foam cells, mast cells, and neutrophilic granulocytes, and the number of 5-lipoxygenase expressing cells markedly increased in advanced lesions. By contrast, reticulocyte-type 15-lipoxygenase was expressed at levels that were several orders of magnitude lower than 5-lipoxygenase in both normal and diseased arteries, and its expression could not be related to lesion pathology. Our data support a model of atherogenesis in which 5-lipoxygenase cascade-dependent inflammatory circuits consisting of several leukocyte lineages and arterial wall cells evolve within the blood vessel wall during critical stages of lesion development. They raise the possibility that antileukotriene drugs may be an effective treatment regimen in late-stage disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.